FDA Approves First Generic Long-Acting HIV Prevention Injectable

The US FDA has approved lenacapavir, the first generic long-acting injectable for HIV prevention, just 16 months after its original approval. This rapid regulatory strategy is expected to significantly reduce costs and increase availability in low- and middle-income countries, marking a key step in global HIV prevention efforts.